In recent years, sodium-glucose cotransporter 2 (SGLT2) inhibitors have been widely used for T2DM management, reducing hyperglycemia by 0.5% to 1.0% 4, 5. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.